Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alzinova

0.41 SEK-1.55 %1.10, 9.49
Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.55 %
-46.80 %
-14.20 %
-30.80 %
-48.66 %
-62.07 %
-81.56 %
-92.84 %
-94.07 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
133.74M SEK
Turnover
184.71K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release01.10.2026, 08.30

The last day of trading in unit rights in Alzinova’s rights issue

Alzinova
Press release01.10.2026, 08.27

DNB Carnegie Access: Alzinova: Supportive early results for diagnostics programme

Alzinova
Regulatory press release30.09.2026, 11.45

Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release24.09.2026, 16.30

Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference

Alzinova
Regulatory press release22.09.2026, 08.30

The subscription period in Alzinovas rights issue of units starts today

Alzinova
Regulatory press release18.09.2026, 08.30

Alzinova publishes information memorandum in connection with rights issue of units

Alzinova
Press release11.09.2026, 13.52

Redeye: Alzinova: Phase II study update and SEK51 rights issue

Alzinova
Press release11.09.2026, 10.20

DNB Carnegie Access: Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital

Alzinova
Regulatory press release10.09.2026, 21.10

The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million

Alzinova
Regulatory press release10.09.2026, 21.05

Alzinova initiates operational start-up of global Phase 2 study with ALZ-101

Alzinova
Press release24.08.2026, 10.02

DNB Carnegie Access: Alzinova: Diagnostics readout next, partner process delayed – Q2 review

Alzinova
Press release20.08.2026, 13.24

Redeye: Alzinova (Q2 Review): Capitalizing on diagnostics opportunities

Alzinova
Regulatory press release20.08.2026, 08.54

Correction: Alzinova publishes interim report for the period January - June 2026

Alzinova
Regulatory press release20.08.2026, 07.45

Alzinova publishes interim report for the period January - June 2026

Alzinova
Press release07.07.2026, 07.09

BioStock: BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B

Alzinova
Press release24.06.2026, 17.37

DNB Carnegie Access: Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds

Alzinova
Regulatory press release24.06.2026, 09.00

Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test

Alzinova
Regulatory press release12.06.2026, 07.30

Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million

Alzinova
Regulatory press release08.06.2026, 16.48

Alzinova announces preliminary outcome of the exercise of warrants of series TO4

Alzinova
Regulatory press release03.06.2026, 08.30

The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026

Alzinova